Closing the Innovation Loop: Mechanistic Trials as a Tool for Precision Medicine in 2026
- Integrating deep multiscalar data sets from biopsy cohort studies (NEPTUNE, KPMP, BEAT-DKD) has allowed to build a molecular map of the kidney in health and disease
- Mechanistic trials with entry and exit biomarkers and biopsies now allow to define treatment responses to experimental therapies
- First success in rare and common diseases will be presented